Immunovant (IMVT) chief technology officer Stout sells $26k in stock

Immunovant, Inc. (NASDAQ:IMVT) Chief Technology Officer Jay S. Stout, sold 1,519 shares of common stock on July 9, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $17.24, for a total value of $26,187. The stock, currently trading at $18.13, has shown strong momentum over the past three months according to InvestingPro data.

The transactions occurred in multiple sales at prices ranging from $17.00 to $17.50. Following the transaction, Stout directly owns 207,724 shares of Immunovant stock, part of the $3.09 billion market cap company. With analyst targets ranging from $17 to $61 per share, InvestingPro analysis indicates the stock is currently fairly valued.

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of 3,436 restricted stock units on July 2, 2025. The company maintains a strong financial position, with more cash than debt on its balance sheet and a healthy current ratio of 11.16, according to InvestingPro research reports.

In other recent news, Immunovant has been in the spotlight with several key developments. The company recently announced that it has six potential indications for its drug candidate IMVT-1402, including treatments for Graves’ Disease, rheumatoid arthritis, and cutaneous lupus erythematosus. H.C. Wainwright adjusted its price target for Immunovant, reducing it from $54.00 to $35.00, while maintaining a Buy rating, indicating confidence in the company’s future potential despite the adjustment. The firm noted Immunovant’s strong cash position of $714 million, which is expected to fund operations through the anticipated study readout in 2027.

Goldman Sachs resumed coverage of Immunovant with a Neutral rating and set a price target of $18.00. The investment bank highlighted IMVT-1402 as a differentiated asset with potential first-in-class applications but expressed concerns about advancing competitive programs. Despite these challenges, Goldman Sachs acknowledged the company’s solid financial backing from majority holder Roivant Sciences (NASDAQ:ROIV), suggesting limited downside risk in the intermediate term. Both analyst firms have recognized the significance of Immunovant’s ongoing clinical development and financial stability as pivotal factors for investors to consider.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.